{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:44:49Z","timestamp":1789501489606,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020193","name":"Novartis Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020193","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001775","name":"University of Technology Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001775","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40273-024-01430-7","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T10:01:54Z","timestamp":1725703314000},"page":"1359-1371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0979-1366","authenticated-orcid":false,"given":"Amy","family":"Gye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"De Abreu Lourenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Goodall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"issue":"7","key":"1430_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21070","volume":"21","author":"R Hettle","year":"2017","unstructured":"Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017;21(7):1\u2013204.","journal-title":"Health Technol Assess"},{"issue":"6","key":"1430_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jval.2019.03.012","volume":"22","author":"MF Drummond","year":"2019","unstructured":"Drummond MF, Neumann PJ, Sullivan SD, et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value Health. 2019;22(6):661\u20138.","journal-title":"Value Health."},{"issue":"1","key":"1430_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jval.2021.07.008","volume":"25","author":"AGS Gye","year":"2021","unstructured":"Gye AGS, De Abreu LR. A systematic review of health technology assessments of chimeric antigen receptor T-cell therapies in young compared with older patients. Value Health. 2021;25(1):47\u201358. https:\/\/doi.org\/10.1016\/j.jval.2021.07.008.","journal-title":"Value Health."},{"issue":"6","key":"1430_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40258-019-00513-3","volume":"17","author":"A Bullement","year":"2019","unstructured":"Bullement A, Cranmer HL, Shields GE. A review of recent decision-analytic models used to evaluate the economic value of cancer treatments. Appl Health Econ Health Policy. 2019;17(6):771\u201380. https:\/\/doi.org\/10.1007\/s40258-019-00513-3.","journal-title":"Appl Health Econ Health Policy"},{"key":"1430_CR5","unstructured":"Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care; a critical review. 2017. Accessed Accessed 27 January 2021 at http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2017\/06\/Partitioned-Survival-Analysis-final-report.pdf."},{"issue":"12","key":"1430_CR6","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","volume":"23","author":"BS Woods","year":"2020","unstructured":"Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23(12):1613\u201321. https:\/\/doi.org\/10.1016\/j.jval.2020.08.2094.","journal-title":"Value Health."},{"issue":"6","key":"1430_CR7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","volume":"15","author":"U Siebert","year":"2012","unstructured":"Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force\u20133. Value Health. 2012;15(6):812\u201320. https:\/\/doi.org\/10.1016\/j.jval.2012.06.014.","journal-title":"Value Health"},{"key":"1430_CR8","unstructured":"York Health Economics Consortium. Discrete event simulation. 2016. https:\/\/yhec.co.uk\/glossary\/discrete-event-simulation\/, accessed 28 January 2021"},{"key":"1430_CR9","unstructured":"Davis S, Stevenson Tappenden P, Wailoo A. NICE DSU technical support document 15: cost-effectiveness modelling using patient-level simulation. 2014. Accessed Accessed 28 January 2021 at http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD15_Patient-level_simulation.pdf."},{"issue":"6","key":"1430_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40273-014-0147-9","volume":"32","author":"J Karnon","year":"2014","unstructured":"Karnon J, Haji Ali Afzali H. When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES. Pharmacoeconomics. 2014;32(6):547\u201358. https:\/\/doi.org\/10.1007\/s40273-014-0147-9.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1430_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989x12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2013overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Mak. 2012;32(5):667\u201377. https:\/\/doi.org\/10.1177\/0272989x12454577.","journal-title":"Med Decis Mak"},{"issue":"1","key":"1430_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2014.12.001","volume":"18","author":"DA Marshall","year":"2015","unstructured":"Marshall DA, Burgos-Liz L, et al. Applying dynamic simulation modeling methods in health care delivery research-the SIMULATE checklist: report of the ISPOR simulation modeling emerging good practices task force. Value Health. 2015;18(1):5\u201316. https:\/\/doi.org\/10.1016\/j.jval.2014.12.001.","journal-title":"Value Health."},{"issue":"5","key":"1430_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"issue":"5","key":"1430_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.Bcd-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein M, Elsallab M, Feldman SA, et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2(5):408\u201322. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-21-0084.","journal-title":"Blood Cancer Discov."},{"issue":"3","key":"1430_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","volume":"36","author":"A Gajra","year":"2022","unstructured":"Gajra A, Zalenski A, Sannareddy A, Jeune-Smith Y, Kapinos K, Kansagra A. Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice. Pharmaceut Med. 2022;36(3):163\u201371. https:\/\/doi.org\/10.1007\/s40290-022-00428-w.","journal-title":"Pharmaceut Med."},{"key":"1430_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.569117","volume":"11","author":"X Xu","year":"2020","unstructured":"Xu X, Huang S, Xiao X, et al. Challenges and clinical strategies of CAR T-cell therapy for acute lymphoblastic leukemia: overview and developments. Front Immunol. 2020;11: 569117. https:\/\/doi.org\/10.3389\/fimmu.2020.569117.","journal-title":"Front Immunol"},{"key":"1430_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01188-w","author":"A Gye","year":"2022","unstructured":"Gye A, Goodall S, De Abreu LR. Cost-effectiveness analysis of tisagenlecleucel versus blinatumomab in children and young adults with acute lymphoblastic leukemia: partitioned survival model to assess the impact of an outcome-based payment arrangement. Pharmacoeconomics. 2022. https:\/\/doi.org\/10.1007\/s40273-022-01188-w.","journal-title":"Pharmacoeconomics"},{"key":"1430_CR18","doi-asserted-by":"crossref","unstructured":"Gye A GS, De Abreu Lourenco R (2024) Discrete event simulation to incorporate infusion wait-time when assessing cost-effectiveness of a chimeric-antigen receptor T-cell therapy. Value Health","DOI":"10.1016\/j.jval.2024.01.008"},{"key":"1430_CR19","unstructured":"Australian Government Department of Health. Technical Guidelines for preparing assessment reports for the Medical Services Advisory Committee - Medical Service Type: Therapeutic (Version 2.0). 2016. http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/9C7DCF1C2DD56CBECA25801000123C32\/$File\/TherapeuticTechnicalGuidelines-Final-March2016-Version2.0-accessible.pdf, Accessed 3 February 2021."},{"issue":"16","key":"1430_CR20","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"issue":"1","key":"1430_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2010.09.020","volume":"47","author":"A von Stackelberg","year":"2011","unstructured":"von Stackelberg A, V\u00f6lzke E, K\u00fchl JS, et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM study group. Eur J Cancer. 2011;47(1):90\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2010.09.020.","journal-title":"Eur J Cancer"},{"issue":"36","key":"1430_CR22","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A Von Stackelberg","year":"2016","unstructured":"Von Stackelberg A, Locatelli F, Zugmaier G. Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381\u20139.","journal-title":"J Clin Oncol"},{"issue":"9757","key":"1430_CR23","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","volume":"376","author":"C Parker","year":"2010","unstructured":"Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376(9757):2009\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(10)62002-8.","journal-title":"Lancet"},{"issue":"4","key":"1430_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/pbc.20922","volume":"48","author":"AC MacArthur","year":"2007","unstructured":"MacArthur AC, Spinelli JJ, Rogers PC, Goddard KJ, Abanto ZU, McBride ML. Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia Canada. Pediatr Blood Cancer. 2007;48(4):460\u20137. https:\/\/doi.org\/10.1002\/pbc.20922.","journal-title":"Pediatr Blood Cancer"},{"key":"1430_CR25","unstructured":"National Institute for Health and Care Excellence. Final appraisal document\u2014Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. NICE; 2018. Accessed 21 December 2020. https:\/\/www.nice.org.uk\/guidance\/ta554\/documents\/final-appraisal-determination-document."},{"key":"1430_CR26","unstructured":"Australian Government Department of Health. Pharmaceutical Benefits Scheme (PBS). Accessed 22 February, 2022. www.pbs.gov.au."},{"key":"1430_CR27","unstructured":"Gordon R, Thompson C, Carolan J, Eckstein G, Rostron C. A costing study of blood and marrow transplantation services in NSW: final report. 2009. Accessed 29 May 2023. https:\/\/ro.uow.edu.au\/cgi\/viewcontent.cgi?referer=&httpsredir=1&article=1496&context=ahsri."},{"issue":"3","key":"1430_CR28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/ejh.13007","volume":"100","author":"LF Casado","year":"2018","unstructured":"Casado LF, Hernandez JA, Jarque I, Echave M, Casado MA, Castro A. Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia. Eur J Haematol. 2018;100(3):264\u201372. https:\/\/doi.org\/10.1111\/ejh.13007.","journal-title":"Eur J Haematol"},{"issue":"3","key":"1430_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.11098","volume":"97","author":"L Sung","year":"2003","unstructured":"Sung L, Buckstein R, Doyle JJ, Crump M, Detsky AS. Treatment options for patients with acute myeloid leukemia with a matched sibling donor. Cancer. 2003;97(3):592\u2013600.","journal-title":"Cancer"},{"key":"1430_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002287","author":"JE Levine","year":"2021","unstructured":"Levine JE, Grupp SA, Pulsipher MA, et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-002287.","journal-title":"J Immunother Cancer"},{"key":"1430_CR31","unstructured":"Latimer N. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2011. Accessed 8 September 2021. http:\/\/www.nicedsu.org.uk"},{"key":"1430_CR32","unstructured":"Australian Government Department of Health. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0). 2016. Accessed 10 November 2021. https:\/\/pbac.pbs.gov.au\/content\/information\/files\/pbac-guidelines-version-5.pdf"},{"key":"1430_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.canep.2018.09.008","volume":"57","author":"K Degeling","year":"2018","unstructured":"Degeling K, Franken MD, May AM, et al. Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. Cancer Epidemiol. 2018;57:60\u20137. https:\/\/doi.org\/10.1016\/j.canep.2018.09.008.","journal-title":"Cancer Epidemiol"},{"key":"1430_CR34","doi-asserted-by":"publisher","DOI":"10.1201\/b19421","volume-title":"Discrete event simulation for health technology assessment","author":"J Caro","year":"2015","unstructured":"Caro J, M\u00f6ller J, Karnon J, Stahl J, Ishak J. Discrete event simulation for health technology assessment. New York: Taylor & Francis; 2015."},{"issue":"11","key":"1430_CR35","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108. https:\/\/doi.org\/10.1097\/00005650-199711000-00002.","journal-title":"Med Care"},{"key":"1430_CR36","unstructured":"Reserve Bank of Australia (RBA). Inflation calculator. Accessed 4 April, 2022. https:\/\/www.rba.gov.au\/calculator\/"},{"key":"1430_CR37","unstructured":"Reserve Bank of Australia (RBA). Exchange rates. Accessed 4 April, 2022. https:\/\/www.rba.gov.au\/statistics\/frequency\/exchange-rates.html"},{"issue":"4","key":"1430_CR38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jval.2024.01.008","volume":"27","author":"A Gye","year":"2024","unstructured":"Gye A, Lourenco RA, Goodall S. Discrete event simulation to incorporate infusion wait-time when assessing cost-effectiveness of a chimeric-antigen receptor T cell therapy. Value Health. 2024;27(4):415\u201324. https:\/\/doi.org\/10.1016\/j.jval.2024.01.008.","journal-title":"Value Health."},{"issue":"1","key":"1430_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40273-019-00845-x","volume":"38","author":"C Smare","year":"2020","unstructured":"Smare C, Lakhdari K, Doan J, Posnett J, Johal S. Evaluating partitioned survival and markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. Pharmacoeconomics. 2020;38(1):97\u2013108. https:\/\/doi.org\/10.1007\/s40273-019-00845-x.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1430_CR40","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1080\/13696998.2020.1796360","volume":"23","author":"H Cranmer","year":"2020","unstructured":"Cranmer H, Shields GE, Bullement A. A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. J Med Econ. 2020;23(10):1176\u201385. https:\/\/doi.org\/10.1080\/13696998.2020.1796360.","journal-title":"J Med Econ"},{"issue":"1","key":"1430_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13561-021-00312-4","volume":"11","author":"S Senanayake","year":"2021","unstructured":"Senanayake S, Graves N, Healy H, Baboolal K, Barnett A, Kularatna S. Time-to-event analysis in economic evaluations: a comparison of modelling methods to assess the cost-effectiveness of transplanting a marginal quality kidney. Health Econ Rev. 2021;11(1):13. https:\/\/doi.org\/10.1186\/s13561-021-00312-4.","journal-title":"Health Econ Rev."},{"issue":"2","key":"1430_CR42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1017\/s0266462314000117","volume":"30","author":"L Standfield","year":"2014","unstructured":"Standfield L, Comans T, Scuffham P. Markov modeling and discrete event simulation in health care: a systematic comparison. Int J Technol Assess Health Care. 2014;30(2):165\u201372. https:\/\/doi.org\/10.1017\/s0266462314000117.","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"1430_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40273-022-01234-7","volume":"41","author":"SP Gavan","year":"2023","unstructured":"Gavan SP, Wright SJ, Thistlethwaite F, Payne K. Capturing the impact of constraints on the cost-effectiveness of cell and gene therapies: a systematic review. Pharmacoeconomics. 2023;41(6):675\u201392. https:\/\/doi.org\/10.1007\/s40273-022-01234-7.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1430_CR44","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40273-019-00801-9","volume":"37","author":"SJ Wright","year":"2019","unstructured":"Wright SJ, Newman WG, Payne K. Accounting for capacity constraints in economic evaluations of precision medicine: a systematic review. Pharmacoeconomics. 2019;37(8):1011\u201327. https:\/\/doi.org\/10.1007\/s40273-019-00801-9.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1430_CR45","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jval.2012.04.013","volume":"15","author":"J Karnon","year":"2012","unstructured":"Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, M\u00f6ller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM modeling good research practices task force\u20134. Value Health. 2012;15(6):821\u20137. https:\/\/doi.org\/10.1016\/j.jval.2012.04.013.","journal-title":"Value Health"},{"issue":"8","key":"1430_CR46","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/j.1524-4733.2010.00775.x","volume":"13","author":"JJ Caro","year":"2010","unstructured":"Caro JJ, M\u00f6ller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health. 2010;13(8):1056\u201360. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00775.x.","journal-title":"Value Health."},{"issue":"2","key":"1430_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00019053-200927020-00006","volume":"27","author":"KN Simpson","year":"2009","unstructured":"Simpson KN, Strassburger A, Jones WJ, Dietz B, Rajagopalan R. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009;27(2):159\u201365. https:\/\/doi.org\/10.2165\/00019053-200927020-00006.","journal-title":"Pharmacoeconomics"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01430-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01430-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01430-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T13:14:58Z","timestamp":1731590098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01430-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01430-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,7]]},"assertion":[{"value":"18 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amy Gye is an employee of Novartis Pharmaceuticals. Stephen Goodall and Richard De Abreu Lourenco have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Concept and design: Gye, Goodall, De Abreu Lourenco; acquisition of data: Gye; analysis and interpretation of data: Gye; drafting of the manuscript: Gye, Goodall, De Abreu Lourenco; critical revision of the paper for important intellectual content: Goodall, De Abreu Lourenco; supervision: Goodall, De Abreu Lourenco.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Individual data used to support this study are not publicly available for ethical and legal reasons. All other sources used in this research are referenced and publicly available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. This research is part of an Industry Doctorate Program at the Centre for Health Economics Research and Evaluation, University of Technology Sydney in collaboration with Novartis Pharmaceuticals Australia. Novartis Pharmaceuticals Australia provided a Research Support Fee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The funder had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation of the manuscript. The manuscript was reviewed by Novartis prior to submitting for publication. The views expressed are those of the authors and not necessarily those of Novartis Pharmaceuticals or the Centre for Health Economics Research and Evaluation (CHERE).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the Funder\/Sponsor"}}]}}